GSK receives European authorisation for once-weekly type 2 diabetes treatment, Eperzan® (albiglutide)

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the European Commission has granted marketing authorisation for its once-weekly diabetes treatment, Eperzan® (albiglutide).
Source: GSK news - Category: Pharmaceuticals Source Type: news